Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21+
SponsorDuke University
About this trial
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Eligibility criteria
Qualifiers
Willing and able to provide informed consent
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
Age 21 years or older, or
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
Disqualifiers
Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
Currently listed for lung transplantation at the time of enrollment
Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
3,000 Participants
are grouped into 3 trial groupsSponsors and collaborators
Duke University
Lead sponsor
Boehringer Ingelheim
Collaborator
Source ClinicalTrials.gov